Sagimet Biosciences Management
Management criteria checks 1/4
Sagimet Biosciences' CEO is Dave Happel, appointed in Oct 2022, has a tenure of 2.25 years. total yearly compensation is $2.69M, comprised of 18.7% salary and 81.3% bonuses, including company stock and options. directly owns 0.044% of the company’s shares, worth $76.75K. The average tenure of the management team and the board of directors is 1.9 years and 2.3 years respectively.
Key information
Dave Happel
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 18.7% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.04% |
| Management average tenure | 1.9yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans
Dec 15
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$38m |
| Jun 30 2024 | n/a | n/a | -US$29m |
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$3m | US$503k | -US$28m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | n/a | n/a | -US$28m |
| Mar 31 2023 | n/a | n/a | -US$28m |
| Dec 31 2022 | US$7m | US$98k | -US$30m |
Compensation vs Market: Dave's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD1.41M).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
CEO
Dave Happel (62 yo)
2.3yrs
Tenure
US$2,685,917
Compensation
Mr. David A. Happel, also known as Dave, has been Chief Executive Officer and Director of Sagimet Biosciences Inc. since October 2022 and serves as its President since October 2022. From March 2020 through...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 9.3yrs | US$930.22k | 0.017% $ 30.2k | |
| CEO, President & Director | 2.3yrs | US$2.69m | 0.044% $ 76.7k | |
| Chief Medical Officer | 3.9yrs | US$1.51m | 0.044% $ 75.4k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| CFO & Principal Accounting Officer | less than a year | no data | no data | |
| General Counsel & Chief Compliance Officer | 1.8yrs | no data | 0.099% $ 171.5k | |
| Senior Vice President of Research & Development | 2yrs | no data | no data | |
| Senior Vice President of New Products | less than a year | no data | no data |
1.9yrs
Average Tenure
61yo
Average Age
Experienced Management: SGMT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 9.3yrs | US$930.22k | 0.017% $ 30.2k | |
| CEO, President & Director | 2.3yrs | US$2.69m | 0.044% $ 76.7k | |
| Independent Director | 17.8yrs | US$14.38k | 0.41% $ 706.9k | |
| Independent Director | 3.8yrs | US$43.00k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0.0068% $ 11.8k | |
| Independent Director | 14.3yrs | US$41.50k | 0.040% $ 68.7k | |
| Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Director | less than a year | no data | no data |
2.3yrs
Average Tenure
60yo
Average Age
Experienced Board: SGMT's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 23:45 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sagimet Biosciences Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrea Tan | Goldman Sachs |
| Andrea Newkirk | Goldman Sachs |
| Antonio Arce | H.C. Wainwright & Co. |